These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 23456393)

  • 1. Pharmacokinetics of intravenous conivaptan in subjects with hepatic or renal impairment.
    Roy MJ; Erdman KA; Abeyratne AT; Plumb LC; Lasseter K; Riff DS; Keirns JJ
    Clin Pharmacokinet; 2013 May; 52(5):385-95. PubMed ID: 23456393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of conivaptan use in patients with severe hepatic impairment.
    Marbury T; Fox J; Kaelin B; Pavliv L
    Drug Des Devel Ther; 2017; 11():373-382. PubMed ID: 28243060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of conivaptan hydrochloride, a vasopressin V(1A)/V(2)-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study.
    Mao ZL; Stalker D; Keirns J
    Clin Ther; 2009 Jul; 31(7):1542-50. PubMed ID: 19695403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia.
    Zeltser D; Rosansky S; van Rensburg H; Verbalis JG; Smith N;
    Am J Nephrol; 2007; 27(5):447-57. PubMed ID: 17664863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous conivaptan.
    Moen MD; Keating GM
    Am J Cardiovasc Drugs; 2008; 8(5):341-8; discussion 349. PubMed ID: 18828645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose comparison of conivaptan (Vaprisol®) in patients with euvolemic or hypervolemic hyponatremia--efficacy, safety, and pharmacokinetics.
    Palmer BF; Rock AD; Woodward EJ
    Drug Des Devel Ther; 2016; 10():339-51. PubMed ID: 26848258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of loading dose and formulation on safety and efficacy of conivaptan in treatment of euvolemic and hypervolemic hyponatremia.
    Kalra S; Efrati S; Arthur JM; Oliven A; Velez JC; McNutt BE; Klasen S; Abeyratne A
    Am J Health Syst Pharm; 2011 Apr; 68(7):590-8. PubMed ID: 21411800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of renal and hepatic impairment on the pharmacokinetic and pharmacodynamic properties and tolerability of fluticasone furoate and vilanterol in combination.
    Allen A; Davis A; Hardes K; Tombs L; Kempsford R
    Clin Ther; 2012 Dec; 34(12):2316-32. PubMed ID: 23200625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron.
    Dickinson J; Lewand M; Sawamoto T; Krauwinkel W; Schaddelee M; Keirns J; Kerbusch V; Moy S; Meijer J; Kowalski D; Morton R; Lasseter K; Riff D; Kupčová V; van Gelderen M
    Clin Drug Investig; 2013 Jan; 33(1):11-23. PubMed ID: 23208320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin.
    Boulton DW; Li L; Frevert EU; Tang A; Castaneda L; Vachharajani NN; Kornhauser DM; Patel CG
    Clin Pharmacokinet; 2011 Apr; 50(4):253-65. PubMed ID: 21348538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of hepatic impairment on the pharmacokinetics of nilotinib: an open-label, single-dose, parallel-group study.
    Yin OQ; Gallagher N; Tanaka C; Fisher D; Sethuraman V; Zhou W; Lin TH; Heuman D; Schran H
    Clin Ther; 2009; 31 Pt 2():2459-69. PubMed ID: 20110053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of Voxelotor in Patients With Renal and Hepatic Impairment.
    Preston RA; Marbury T; Balaratnam G; Green M; Dixon S; Lehrer-Graiwer J; Washington C
    J Clin Pharmacol; 2021 Apr; 61(4):493-505. PubMed ID: 33084052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of 30-minute infusions of conivaptan in euvolemic and hypervolemic hyponatremia.
    Koren MJ; Hamad A; Klasen S; Abeyratne A; McNutt BE; Kalra S
    Am J Health Syst Pharm; 2011 May; 68(9):818-27. PubMed ID: 21515866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conivaptan: new treatment for hyponatremia.
    Walter KA
    Am J Health Syst Pharm; 2007 Jul; 64(13):1385-95. PubMed ID: 17592003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and Safety of DS-8500a, an Antidiabetic Drug, in Japanese Subjects with Hepatic or Renal Impairment: A Single-Center, Open-Label, Single-Dose Study.
    Kato M; Ishizuka H; Taguchi T; Shiosakai K; Kamiyama E; Sata M; Yoshida T
    Adv Ther; 2018 Aug; 35(8):1239-1250. PubMed ID: 29968010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Asenapine pharmacokinetics in hepatic and renal impairment.
    Peeters P; Bockbrader H; Spaans E; Dogterom P; Lasseter K; Marbury T; Gibson GL; de Greef R
    Clin Pharmacokinet; 2011 Jul; 50(7):471-81. PubMed ID: 21651314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia.
    Ghali JK; Koren MJ; Taylor JR; Brooks-Asplund E; Fan K; Long WA; Smith N
    J Clin Endocrinol Metab; 2006 Jun; 91(6):2145-52. PubMed ID: 16522696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and safety of revefenacin in subjects with impaired renal or hepatic function.
    Borin MT; Lo A; Barnes CN; Pendyala S; Bourdet DL
    Int J Chron Obstruct Pulmon Dis; 2019; 14():2305-2318. PubMed ID: 31632000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic and pharmacodynamic properties of eptifibatide in subjects with normal or impaired renal function.
    Gretler DD; Guerciolini R; Williams PJ
    Clin Ther; 2004 Mar; 26(3):390-8. PubMed ID: 15110131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of vilazodone in patients with mild or moderate renal impairment.
    Boinpally R; Alcorn H; Adams MH; Longstreth J; Edwards J
    Clin Drug Investig; 2013 Mar; 33(3):199-206. PubMed ID: 23417352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.